European Spine Journal

, Volume 15, Issue 6, pp 944–952

Recombinant coagulation factor VIIa—a novel haemostatic agent in scoliosis surgery?

  • Maciej Kolban
  • Ina Balachowska-Kosciolek
  • Michal Chmielnicki
Original Article

Astract

Spinal fusion surgery in children and adolescents with idiopathic scoliosis is often associated with severe haemorrhage. Recombinant coagulation factor VIIa (rFVIIa) has previously been shown to be an effective haemostatic treatment for severe bleeding associated with a variety of coagulopathic and non-coagulopathic indications. The aim of this retrospective study was to assess the safety and haemostatic efficacy of rFVIIa in a series of 26 consecutive adolescent patients with scoliosis (22 females; mean age 16.6 years) undergoing correctional surgery. A second series of 26 consecutive patients (20 females; mean age 16.2 years) who received standard therapy during surgery, represented historical controls. Blood loss, transfusion requirements, duration of surgery, and peri-operative measurements of coagulation parameters were compared between the two groups. Intra-operative and combined intra-operative and post-operative blood losses were significantly smaller in the rFVIIa-treatment group than in the historical controls (P=0.003 and 0.032, respectively); rFVIIa-treated patients also demonstrated significantly reduced blood loss per vertebral segment fused (P=0.032) and per hour of surgery (P<0.001). Intra-operative requirements for packed red blood cells were also significantly lower in the treatment group (P=0.042). Patients in the treatment group demonstrated rapid and maintained reduction of prothrombin time and international normalised ratio; values among rFVIIa-treated patients remained significantly lower than those in the control group at all time points evaluated (P<0.001). There were no deaths and no adverse events. These results suggest that rFVIIa is a safe and effective haemostatic agent for use during spinal fusion surgery in adolescent patients with idiopathic scoliosis; however, further research and randomised, placebo-controlled trials are needed to confirm these findings.

Keywords

Bleeding Haemostasis Scoliosis Surgery RFVIIa 

References

  1. 1.
    Aldouri M (2002) The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophilic patients. Pathophysiol Haemost Thromb 32(Suppl 1):41–46PubMedGoogle Scholar
  2. 2.
    Anand N, Idio FG, Remer S, Hoppenfeld S (1998) The effects of peri-operative blood salvage and autologous blood donation on transfusion requirements in scoliosis surgery. J Spinal Disord 11:532–534PubMedGoogle Scholar
  3. 3.
    Brecher ME, Monk T, Goodnough LT (1997) A standardized method for calculating blood loss. Transfusion 37:1070–1074CrossRefPubMedGoogle Scholar
  4. 4.
    Chuansumrit A, Suwannuraks M, Sri-Udomporn N, Pongtanakul B, Worapongpaiboon S (2003) Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 14:187–190CrossRefPubMedGoogle Scholar
  5. 5.
    Cole JW, Murray DJ, Snider RJ et al (2003) Aprotinin reduces blood loss during spinal surgery in children. Spine 28:2482–2485CrossRefPubMedGoogle Scholar
  6. 6.
    Copley LAB, Richards BS, Safavi FZ, Newton PO (1999) Hemodilution as a method to reduce transfusion requirements in adolescent spine fusion surgery. Spine 24:219–224CrossRefPubMedGoogle Scholar
  7. 7.
    d’Oiron R, Menart C, Trzeciak MC, et al (2000) Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann’s thrombasthenia undergoing invasive procedures. Thromb Haemost 83:644–647PubMedGoogle Scholar
  8. 8.
    Eikelboom JW, Bird R, Blythe D, et al (2003) Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 14:713–717CrossRefPubMedGoogle Scholar
  9. 9.
    Florentino-Pineda I, Blakemore LC, Thompson GH, et al (2001) The effect of E-aminocaproic acid on perioperative blood loss in patients with idiopathic scoliosis undergoing posterior spinal fusion. Spine 26:1147–1151CrossRefPubMedGoogle Scholar
  10. 10.
    Friederich PW, Henny CP, Messelink EJ, et al (2003) Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 361:201–205CrossRefPubMedGoogle Scholar
  11. 11.
    Gross JB (1983) Estimating allowable blood loss: corrected for dilution. Anesthesiology 58:277–280PubMedGoogle Scholar
  12. 12.
    Guay J, Haig M, Lortie L, Guertin M-C, Poitras B (1994) Predicting blood loss in surgery for idiopathic scoliosis. Can J Anaesth 41:775–781PubMedGoogle Scholar
  13. 13.
    Guillet B, Pinganaud C, Proulle V, Dreyfus M, Lambert T (2002) Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII. Thromb Haemost 88:698–699PubMedGoogle Scholar
  14. 14.
    Hedner U (2000) NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis 11:107–111PubMedGoogle Scholar
  15. 15.
    Hoffman M (2003) A cell-based model of coagulation and the role of factor VIIa. Blood Rev 17:S1–S5CrossRefPubMedGoogle Scholar
  16. 16.
    Huang WY, Kruskall MS, Bauer KA, Uhl L, Shaz BH (2004) The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency. Transfusion 44:1562–1566CrossRefPubMedGoogle Scholar
  17. 17.
    Hunault M, Bauer KA (2000) Recombinant factor VIIa for the treatment of congenital factor VII deficiency. Semin Thromb Hemost 26:401–405PubMedGoogle Scholar
  18. 18.
    Kannan S, Meert KL, Mooney JF, Hillman-Wiseman C, Warrier I (2002) Bleeding and coagulation changes during spinal fusion surgery: a comparison of neuromuscular and idiopathic scoliosis patients. Pediatr Crit Care Med 3:364–369CrossRefPubMedGoogle Scholar
  19. 19.
    Letts M, Pang E, D’Astrous J, et al (1998) The influence of desmopressin on blood loss during spinal fusion surgery in neuromuscular patients. Spine 23:475–478CrossRefPubMedGoogle Scholar
  20. 20.
    Levi M, Peters M, Büller HR (2005) Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 33:883–890CrossRefPubMedGoogle Scholar
  21. 21.
    Martinowitz U, Kenet G, Segal E, et al (2001) Recombinant activated rFVIIa for adjunctive haemorrhage control in trauma. J Trauma 51:431–438PubMedGoogle Scholar
  22. 22.
    Mayer SA, Brun NC, Begtrup K, et al (2005) Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352:777–786CrossRefPubMedGoogle Scholar
  23. 23.
    McCall RE, Bilderback KK (1997) Use of intravenous premarin to decrease postoperative blood loss after pediatric scoliosis surgery. Spine 22:1394–1397CrossRefPubMedGoogle Scholar
  24. 24.
    McNeill TW, DeWald RL, Kuo KN, Bennett EJ, Salem MR (1974) Controlled hypotensive anesthesia in scoliosis surgery. J Bone Joint Surg Am 56:1167–1172PubMedGoogle Scholar
  25. 25.
    Mercuriali F, Inghilleri G (1996) Proposal of an algorithm to help the choice of best transfusion strategy. Curr Med Res Opin 13:465–478PubMedGoogle Scholar
  26. 26.
    Monroe DM, Hoffman M, Oliver JA, Roberts HR (1998) A possible mechanism of action of factor VIIa independent of tissue factor. Blood Coagul Fibrinolysis 9:S15–S20PubMedGoogle Scholar
  27. 27.
    Mullighan CG, Rischbieth A, Duncan EM, Lloyd JV (2004) Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven). Blood Coagul Fibrinolysis 15:347–351CrossRefPubMedGoogle Scholar
  28. 28.
    Murray DJ, Forbes RB, Titone MB, Weinstein SL (1997) Transfusion management in pediatric and adolescent scoliosis surgery. Spine 22:2735–2740CrossRefPubMedGoogle Scholar
  29. 29.
    Murray DJ, Pennell BJ, Weinstein SL, et al (1995) Packed red cells in acute blood loss: Dilutional coagulopathy as a cause of surgical bleeding. Anesth Analg 80:336–342CrossRefPubMedGoogle Scholar
  30. 30.
    Park KS, Lim YJ, Do SH (2004) Combined use of autologous transfusion techniques to avoid allogeneic transfusion in spinal fusion surgery with instrumentation. Int J Clin Pract 58:260–263CrossRefPubMedGoogle Scholar
  31. 31.
    Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT (2003) Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 53:34–39CrossRefPubMedGoogle Scholar
  32. 32.
    Patel NJ, Patel BS, Paskin S, Laufer S (1985) Induced moderate hypotensive anesthesia for spinal fusion and Harrington-rod instrumentation. J Bone Joint Surg Am 67:1384–1387PubMedGoogle Scholar
  33. 33.
    Peerlinck K, Vermylen J (1999) Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost 82:1775–1776PubMedGoogle Scholar
  34. 34.
    Peleg I, Eldor A, Kahane I, et al (1989) Altered structural and functional properties of myosins, from platelets of idiopathic scoliosis patients. J Orthop Res 7:260–265CrossRefPubMedGoogle Scholar
  35. 35.
    Phillips WA, Hensinger RN (1988) Control of blood loss during scoliosis surgery. Clin Orthop 229:88–93PubMedGoogle Scholar
  36. 36.
    Poon MC, Demers C, Jobin F, Wu JW (1999) Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 94:3951–3953PubMedGoogle Scholar
  37. 37.
    Poon MC, d’Oiron R, Hann I, et al (2001) Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol 38:21–25CrossRefGoogle Scholar
  38. 38.
    Renkens KL Jr, Payner TD, Leipzig TJ, et al (2001) A multicenter, prospective, randomized trial evaluating a new haemostatic agent for spinal surgery. Spine 26:1645–1650CrossRefPubMedGoogle Scholar
  39. 39.
    Roberts HR, Monroe DM III, Hoffman M (2004) Safety profile of recombinant factor VIIa. Sem Hematol 41(Suppl 1):101–108CrossRefGoogle Scholar
  40. 40.
    Sabel M, Stummer W (2004) The use of local agents: Surgicel and Surgifoam. Eur Spine J 13(Suppl 1):S97–S101CrossRefPubMedGoogle Scholar
  41. 41.
    Scharrer I (1999) Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 5:253–259CrossRefPubMedGoogle Scholar
  42. 42.
    Uden A, Nilsson IM, Willner S (1980) Collagen-induced platelet aggregation and bleeding time in adolescent idiopathic scoliosis. Acta Orthop Scand 51:773–777PubMedGoogle Scholar
  43. 43.
    Wang YR, Liu YC, Chung NC, et al (2003) Inferior vena cava tear during posterior spinal fusion surgery. Acta Anaesthesiol Sin 41:89–92PubMedGoogle Scholar
  44. 44.
    Yarom R, Muhlrad A, Hodges S, Robin GC (1980) Platelet pathology in patients with idiopathic scoliosis: ultrastructural morphology, aggregations, x-ray spectrometry, and biochemical analysis. Lab Invest 43:208–216PubMedGoogle Scholar
  45. 45.
    Zheng F, Cammisa FP, Sandhu HS, Girardi FP, Khan SN (2002) Factors predicting hospital stay, operative time, blood loss, and transfusion in patients undergoing revision posterior lumbar spine decompression, fusion, and segmental instrumentation. Spine 8:818–824CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Maciej Kolban
    • 1
  • Ina Balachowska-Kosciolek
    • 2
  • Michal Chmielnicki
    • 1
  1. 1.Public Clinical Hospital No. 1Children’s Orthopaedic ClinicPoland
  2. 2.Children’s Hospital Intensive Care UnitPoland

Personalised recommendations